ESMO精准医学工作组:新抗原预测的计算方法及临床获益建议
该文由ESMO精准医学工作组制定,系统综述新抗原预测的计算流程与科学证据,指出多数流程提供肽-MHC结合亲和力预测,新近方法纳入变异等位基因频率、基因表达和突变克隆性等特征。文章强调需改进肿瘤特异性新抗原的识别、选择与优先级排序,以扩大疫苗和过继T细胞疗法的获益范围。
要点
- 新抗原预测计算流程多基于肽-MHC结合亲和力,新方法整合变异等位基因频率、表达与克隆性。
- 新抗原可在高及低肿瘤突变负荷的癌种中预测,部分利用移码、剪接变体、基因融合等肿瘤特异性异常。
- 需改进新抗原识别与优先级排序,以提升疫苗和过继T细胞疗法的临床获益。
核心结论
- 改进肿瘤特异性新抗原的识别、选择与优先级排序,是扩大癌症疫苗和过继T细胞疗法获益范围的关键。
研究设计与样本
- ESMO精准医学工作组发起的推荐性文章,包含对新抗原预测现有框架的概述与对当前科学证据的系统综述。
主要发现
- 现有多种新抗原预测计算流程,多数提供肽-MHC结合亲和力预测。
- 较新方法纳入变异等位基因频率、基因表达和突变克隆性等额外特征。
- 新抗原可在所有癌种中预测,包括高和低肿瘤突变负荷的癌种。
- 可部分利用移码突变、剪接变体、基因融合、内源性逆转录元件等肿瘤特异性异常预测新抗原。
- 正在进行的临床试验将揭示哪些癌种和免疫治疗组合从新抗原免疫治疗中获益最大。
临床怎么用
- 临床选择新抗原预测流程时,可关注是否整合变异等位基因频率、基因表达和克隆性等特征。
- 对高及低肿瘤突变负荷癌种均可开展新抗原预测,并关注移码、剪接变体、基因融合等肿瘤特异性异常来源。
局限性
- 文章未报告预测流程的具体性能数值、阈值或临床疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of next-generation sequencing technologies has enabled the rapid identification of non-synonymous somatic mutations in cancer cells. Neoantigens are mutated peptides derived from somatic mutations not present in normal tissues that may result in the presentation of tumour-specific peptides capable of eliciting antitumour T-cell responses. Personalised neoantigen-based cancer vaccines and adoptive T-cell therapies have been shown to prime host immunity against tumour cells and are under clinical trial development. However, the optimisation and standardisation of neoantigen identification, as well as its delivery as immunotherapy are needed to increase tumour-specific T-cell responses and, thus, the clinical efficacy of current cancer immunotherapies. METHODS: In this recommendation article, launched by the European Society for Medical Oncology (ESMO), we outline and discuss the available framework for neoantigen prediction and present a systematic review of the current scientific evidence. RESULTS: A number of computational pipelines for neoantigen prediction are available. Most of them provide peptide major histocompatibility complex (MHC) binding affinity predictions, but more recent approaches incorporate additional features like variant allele fraction, gene expression, and clonality of mutations. Neoantigens can be predicted in all cancer types with high and low tumour mutation burden, in part by exploiting tumour-specific aberrations derived from mutational frameshifts, splice variants, gene fusions, endogenous retroelements and other tumour-specific processes that could yield more potently immunogenic tumour neoantigens. Ongoing clinical trials will highlight those cancer types and combinations of immune therapies that would derive the most benefit from neoantigen-based immunotherapies. CONCLUSIONS: Improved identification, selection and prioritisation of tumour-specific neoantigens are needed to increase the scope of benefit from cancer vaccines and adoptive T-cell therapies. Novel pipelines are being developed to resolve the challenges posed by high-throughput sequencing and to predict immunogenic neoantigens.
引用
- De Mattos-Arruda L, Vazquez M, Finotello F, et al. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2020. PMID: 32610166. doi:10.1016/j.annonc.2020.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。